1274-IMIREG: Regulon Signature of Immunotherapy Response
Researchers have developed IMIREG, a novel 14-regulon transcriptional signature designed to predict how patients with various cancers will respond to immune checkpoint blockade (ICB). By utilizing a systems-biology approach to infer the activity of master transcription factors, this biomarker moves beyond simple immune cell counts to capture the actual regulatory circuitry of the tumor microenvironment. Validation across 50 clinical trial datasets demonstrated that IMIREG consistently identifies responders and outperforms established signatures like IFN-γ and T cell-inflamed profiles…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.